PLG and ovarian carcinoma: Recently, problems with sustained production of antiangiogenic proteins were overcome by adeno-associated virus-mediated intratumoural delivery (Ma et al, 2002b) or systemic delivery through intramuscular injection of angiostatin for treatment of intracranial tumours (Ma et al, 2002a) or endostatin for treatment of ovarian carcinoma (Subramanian et al, 2006).